IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
Provided By PR Newswire
Last update: Mar 27, 2025
Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy
Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024
Read more at prnewswire.com
